Gilead Sciences (GILD) Earnings Date & Reports

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

GILD is expected to report earnings to rise 8.29% to $1.96 per share on August 05

Gilead Sciences GILD Stock Earnings Reports

Q2'25

Est.

$1.96

Q1'25

Beat

by $0.04

Q4'24

Beat

by $0.19

Q3'24

Beat

by $0.51

Q2'24

Beat

by $0.41

The last earnings report on April 24 showed earnings per share of $1.81, beating the estimate of $1.77. With 13.14M shares outstanding, the current market capitalization sits at 90.79B.

View a ticker or compare two or three

Compare

GILD